TherapeuticsMD, Inc. (NYSE MKT: TXMD) announced today the pricing of an underwritten offering of 13,750,000 shares of its common stock, offered at a price of $2.40 per share. The gross proceeds to TherapeuticsMD from this offering are expected to be approximately $33 million, before deducting underwriting discounts, commissions, and other estimated offering expenses payable by TherapeuticsMD. All of the shares in the offering are to be sold by TherapeuticsMD. The offering is expected to close on or about September 30, 2013, subject to the satisfaction of customary closing conditions. Stifel, Cowen and Company, and Lazard Capital Markets acted as joint book-running managers for the offering. Noble Financial Capital Markets served as financial advisor for the transaction. A shelf registration statement on Form S-3 relating to the offering of the shares of common stock described above was filed with the Securities and Exchange Commission ("SEC") and declared effective by the SEC. A prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov. When available, copies of the prospectus supplement may also be obtained from Stifel, Nicolaus & Company, Incorporated, Attn: Syndicate, One Montgomery Street, 36th Floor, San Francisco, CA 94104, by telephone at (415) 364-2720 or by e-mail at email@example.com; from Cowen and Company, LLC c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department or by telephone at (631) 274-2806; and from Lazard Capital Markets LLC, 30 Rockefeller Plaza, New York, NY 10020 or via telephone at (800) 542-0970. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.